BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in combination with a PD-1 inhibitor, retifanlimab (provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for advanced breast cancer. For additional information on BriaCell, please visit our website: http://briacell.com/

Prevail Partners

Additional survival updates and clinical data sets on BriaCell's entire Phase 2 study cohort will be presented at the San Antonio Breast Cancer Symposium® on December 6th and 7th, 2023. https://bit.ly/3uE9n0q

Dr. William V. Williams, President and CEO of BriaCell, emphasizes importance of the new remarkable responder in our Phase 2 study of the Bria-IMT™ combination regimen. Learn more: https://bit.ly/3uE9n0q

After only 3 cycles, the patient in BriaCell's Phase 2 study of the Bria-IMT™ combination regimen experienced a remarkable improvement of eye-bulging “proptosis” caused by an orbital metastatic #breastcancer tumor behind the eye. Find more information: https://bit.ly/3uE9n0q

Carmen Calfa, M.D., Clinical Research Lead for the breast site disease group at the University of Miami Miller School of Medicine, Co-Director of the Cancer Survivorship Program at Sylvester Comprehensive Cancer Center, and Principal Clinical Investigator of the Phase 2 Bria-IMT™ study highlights BriaCell's new remarkable responder in our Phase 2 study of the Bria-IMT™ combination regimen. https://bit.ly/3uE9n0q

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is thrilled to announce a new remarkable responder in our Phase 2 study of the Bria-IMT™ combination regimen. The patient, who had previously failed all available therapies, had cancer behind the eye, causing proptosis (eye-bulging) and significant pain that were both resolved with BriaCell's treatment. For additional details, visit: https://bit.ly/3uE9n0q

Bria-IMT™ and Bria-OTS™ show great potential as targeted #immunotherapies in our ongoing battle against #breastcancer. For more information, visit: https://bit.ly/47o2fE3

COM:BRIACELL